
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx is showing signs of a transitional period as it focuses on operational discipline and commercial reacceleration. Despite modest annual growth, the company's fourth quarter financial results were weaker due to underperformance in the US market. However, the recent cost restructuring and improved margins, along with a secured credit facility, indicate a positive step towards stabilizing operations and achieving sustainable profitability in the future.
Bears say
Pulmonx is facing multiple risk factors that could negatively impact its future financial performance, such as potential clinical or regulatory setbacks, partnership and financial risks, and market share risk. The company's Q1 results were disappointing due to a decline in U.S. sales and the absence of China sales, and its full-year revenue guidance is below expectations. Furthermore, Pulmonx has a history of consistent losses and significant cash burn, which raises concerns about its long-term financial sustainability.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares